The Chemours Company $CC Shares Acquired by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. lifted its position in shares of The Chemours Company (NYSE:CC) by 150.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,082 shares of the specialty chemicals company’s stock after acquiring an additional 120,832 shares during the quarter. Pekin Hardy Strauss Inc.’s holdings in Chemours were worth $2,729,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. purchased a new position in Chemours in the 2nd quarter valued at approximately $34,000. Allworth Financial LP acquired a new position in Chemours during the second quarter worth $51,000. State of Wyoming acquired a new position in Chemours during the second quarter worth $67,000. Sterling Capital Management LLC boosted its position in Chemours by 839.3% during the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock worth $69,000 after purchasing an additional 4,532 shares in the last quarter. Finally, Nykredit A S purchased a new stake in Chemours during the second quarter worth $99,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Insider Buying and Selling at Chemours

In related news, CEO Denise Dignam acquired 3,378 shares of Chemours stock in a transaction dated Tuesday, August 11th. The shares were acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the transaction, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were bought at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the purchase, the insider owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. The trade was a 3.42% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.85% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have weighed in on CC. The Goldman Sachs Group reissued a “neutral” rating and issued a $16.00 target price on shares of Chemours in a report on Friday, October 9th. BMO Capital Markets cut their price target on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Royal Bank Of Canada lowered shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price objective on the stock. in a research report on Tuesday, October 13th. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 10th. Finally, UBS Group dropped their target price on shares of Chemours from $16.00 to $15.00 and set a “neutral” rating for the company in a report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Chemours has an average rating of “Hold” and a consensus target price of $17.45.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions for AI data centers, which the company says can improve efficiency and reduce water use. The launch gives investors a potential growth opportunity in a fast-growing market. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Analyst views remain mixed: Barclays maintained a Hold rating, UBS kept Neutral while trimming its price target to $15, and Truist lowered its target to $18 but retained a Buy rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Multiple law firms publicized a securities class action against Chemours, with a December 7 lead-plaintiff deadline. The lawsuit alleges the company misrepresented 2026 EBITDA guidance by not accounting for distributor pre-buying that shifted about $65 million in Opteon refrigerant sales from 2026 into 2025. The allegations have not been proven, but the case adds legal and reputational risk. Article: SueWallSt Reminds Shareholders of Lead Plaintiff Deadline
• Negative Sentiment: Recent quarterly results also provide a headwind: Chemours reported EPS of $0.21, below the $0.26 consensus and down from $0.40 a year earlier, despite revenue modestly exceeding estimates. The earnings shortfall and concerns about refrigerant demand may be contributing to investor caution.

Chemours Trading Down 7.4%

Shares of Chemours stock opened at $12.77 on Friday. The Chemours Company has a 1 year low of $10.44 and a 1 year high of $28.67. The company has a debt-to-equity ratio of 24.25, a current ratio of 1.81 and a quick ratio of 0.88. The business has a 50 day moving average price of $14.02 and a 200 day moving average price of $18.23. The company has a market capitalization of $1.92 billion, a P/E ratio of -12.51 and a beta of 1.47.

Chemours (NYSE:CC) last announced its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. Chemours’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.40 EPS. Sell-side analysts anticipate that The Chemours Company will post 0.81 EPS for the current fiscal year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s payout ratio is -34.31%.

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.